Palbociclib, trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A randomized phase II trial

Simple item page
dc.conference.dateMAY 23-24, 2020
dc.conference.titleESMO Breast Cancer Virtual Meeting
dc.contributor.authorCiruelos, E. M.
dc.contributor.authorVillagrasa, P.
dc.contributor.authorOliveira, M.
dc.contributor.authorPernas Simon, S.
dc.contributor.authorCortes, J.
dc.contributor.authorVazquez, S.
dc.contributor.authorMartinez, N.
dc.contributor.authorPerello, A.
dc.contributor.authorBermejo De Las Heras, B.
dc.contributor.authorMartinez, E.
dc.contributor.authorGarau Llinas, I.
dc.contributor.authorMele Olive, M.
dc.contributor.authorMontano, A.
dc.contributor.authorVega, E.
dc.contributor.authorCantos, B.
dc.contributor.authorEcharri, M. J.
dc.contributor.authorPascual, T.
dc.contributor.authorCeliz, P.
dc.contributor.authorGonzalez-Farre, X.
dc.contributor.authorPrat, A.
dc.contributor.authoraffiliation[Ciruelos, E. M.] Hosp 12 Octubre, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Villagrasa, P.] SOLTI, Breast Canc Res Grp, Barcelona, Spain
dc.contributor.authoraffiliation[Oliveira, M.] Vall Hebron Univ Hosp, Dept Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Oliveira, M.] Vall dHebron Inst Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Pernas Simon, S.] Hosp Duran & Reynals, ICO Inst Catala Oncol Hospitalet, Med Oncol Breast Unit, Lhospitalet De Llobregat, Spain
dc.contributor.authoraffiliation[Cortes, J.] IOB Inst Oncol, Quiron Grp, Dept Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Vazquez, S.] Hosp Duran & Reynals, ICO Inst Catala Oncol Hospitalet, Med Oncol Breast, Lhospitalet De Llobregat, Spain
dc.contributor.authoraffiliation[Martinez, N.] Ramon & Cajal Hosp, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Perello, A.] Hosp Univ Son Espases, Dept Med Oncol, Palma De Mallorca, Spain
dc.contributor.authoraffiliation[Bermejo De Las Heras, B.] Hosp Clin Univ Valencia, Dept Med Oncol, Valencia, Spain
dc.contributor.authoraffiliation[Martinez, E.] Consorcio Hosp Prov Castellon, Dept Med Oncol, Castellon de La Plana, Spain
dc.contributor.authoraffiliation[Garau Llinas, I.] Hosp Son Llatzer, Dept Med Oncol, Palma De Mallorca, Spain
dc.contributor.authoraffiliation[Mele Olive, M.] Hosp Univ St Joan de Reus, Dept Med Oncol, Reus, Spain
dc.contributor.authoraffiliation[Montano, A.] Hosp Univ Virgen Rocio, Dept Med Oncol, Seville, Spain
dc.contributor.authoraffiliation[Vega, E.] Ctr Integral Oncol Clara Campal, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Cantos, B.] Hosp Univ Puerta Hierro Majadahonda, Dev Med Oncol, Majadahonda, Spain
dc.contributor.authoraffiliation[Echarri, M. J.] Hosp Severo Ochoa, Dept Med Oncol, Leganes, Spain
dc.contributor.authoraffiliation[Pascual, T.] Hosp Clin Barcelona, Med Oncol Dept, Barcelona, Spain
dc.contributor.authoraffiliation[Prat, A.] Hosp Clin Barcelona, Med Oncol Dept, Barcelona, Spain
dc.contributor.authoraffiliation[Celiz, P.] SOLTI Breast Canc Res Grp, Dept Sci, Barcelona, Spain
dc.contributor.authoraffiliation[Gonzalez-Farre, X.] Hosp Gen Cataluna, Dept Med Oncol, San Cugat Del Valles, Spain
dc.contributor.funderPfizer
dc.date.accessioned2025-01-07T15:32:01Z
dc.date.available2025-01-07T15:32:01Z
dc.date.issued2020-05-01
dc.identifier.doi10.1016/j.annonc.2020.03.280
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753420363596/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27212
dc.identifier.wosID538879300160
dc.issue.number2
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.page.numberS80-S81
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titlePalbociclib, trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A randomized phase II trial
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía